But the investors at Arch Venture Partners are instead driven by frustration. Cofounder Robert Nelsen told reporters he was upset when hearing about shortages of COVID-19 treatments, surgical ...

The company is developing a care program focused on… Read More ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund ...

Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday. The terms of the IPO were not disclosed in the ...

The initial funding was led by Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors, according to a Jan. 8 release. Tenvie did not specify ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Almost five years after leaving Spark Therapeutics, Dr. Katherine High is back at the helm of a gene therapy company with ...

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and ...